Sibutramine hydrochloride was formerly used as a weight-loss medication; it functions by inhibiting the reuptake of norepinephrine, serotonin, and dopamine, thereby increasing energy expenditure and promoting weight loss. However, this pharmacological action is accompanied by significant cardiovascular risks. Extensive clinical studies have demonstrated that patients taking this drug face a higher risk of serious cardiovascular events compared to those receiving a placebo. Consequently, numerous countries and regions worldwide have banned or restricted its use, as its associated risks are deemed to outweigh its benefits. The risks associated with using this medication are particularly elevated in children-whose cardiovascular systems are still in the developmental stage-and its use in this population should be strictly avoided, with priority given to non-pharmacological interventions. For patients with underlying medical conditions, use of the drug increases the likelihood of cardiovascular events; therefore, decisions regarding its use must be made with extreme caution following a professional medical assessment. Furthermore, use by pregnant or breastfeeding women may have adverse effects on the fetus or infant and should therefore be avoided.
Brief Summary of Pharmacological Action
Sibutramine hydrochloride was formerly utilized as a weight-loss medication. Its mechanism of action involves inhibiting the reuptake of norepinephrine, serotonin, and dopamine, thereby increasing energy expenditure and exerting a weight-reducing effect; however, this pharmacological action is accompanied by significant cardiovascular risks.